Clinical trials: Walking
Multiple Sclerosis, Walking Impairment
A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
This study assessed the long-term safety and tolerability of ADS-5102 in subjects with MS and walking impairment who had completed the double-blind, placebo-controlled study of ADS-5102 in subjects with MS (ADS-AMT-301).
- Trial name
- NCT03567057
- Testing
- ADS-5102, 274 mg
- Where
- 92 sites in United States, Canada
- Volunteers
- 424 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Walking Impairment, Multiple Sclerosis
Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment
This study assessed the efficacy and safety of ADS-5102 (at daily doses of 137 mg or 274 mg) compared with placebo in MS patients with walking impairment.
- Trial name
- NCT03436199
- Testing
- ADS-5102, 137 mg, ADS-5102, 274 mg
- Where
- 84 sites in United States, Canada
- Volunteers
- 558 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Peripheral Vascular Disease, Intermittent Claudication
Intermittent Negative Pressure; Impact on Peripheral Artery Disease and Intermittent Claudication
The objective is to ensure the pro-active collection of information on quality, safety and performance of FlowOx™ after it is placed on the market.
- Conditions
- Peripheral Vascular Disease, Intermittent Claudication, Walking, Difficulty, Critical Limb Ischemia
- Trial name
- FlowOx (NCT04100681)
- Testing
- Active FlowOx™
- Where
- 5 sites in Germany
- Volunteers
- 16 people
- Sponsor
- Otivio AS
Walking Impairment, Multiple Sclerosis
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed once daily at bedtime for the…
- Trial name
- NCT02471222
- Testing
- ADS-5102
- Where
- 15 sites in United States
- Volunteers
- 60 people
- Sponsor
- Adamas Pharmaceuticals, Inc.